Amer Zeidan: How well does Allogeneic Hematopoietic Cell Transplantation (AlloHCT) work for Blastic Plasmacytoid Dendritic Cell Neoplasm BPDCNsm?

Amer Zeidan, recently tweeted:

“How well does Allogeneic Hematopoietic Cell Transplantation (AlloHCT) work for Blastic Plasmacytoid Dendritic Cell Neoplasm BPDCNsm? Our new CIBMTR analysis with many outstanding investigators.”

For the article click here.
Source: Amer Zeidan/Twitter

Amer Zeidan is an Associate Professor of Medicine (Hematology) at Yale University. He is also the medical director of Hematology Early Therapeutics Research, the leader of the Myeloid Malignancies DART (Disease Aligned Research Team), and the director of Continuing Medical Education (CME) at the Hematology division and chairs the Protocol Review Committee (PRC) at Yale Cancer Center. Dr. Zeidan is a well-known leukemia researcher with a special focus on targeted therapies and immunotherapy for myeloid malignancies, and a social media influencer in the field of blood cancer.